BioCentury
ARTICLE | Politics & Policy

Massachusetts negotiates HCV discounts

July 2, 2016 12:01 AM UTC

MassHealth, Massachusetts' state Medicaid program, said drug makers Gilead Sciences Inc. (NASDAQ:GILD) and Bristol-Myers Squibb Co. (NYSE:BMY) agreed to provide rebates that would give all MassHealth members access to HCV drugs when medically necessary. The deal could create pressure for the companies to strike similar deals in other states.

Gilead's Harvoni ledipasvir/ sofosbuvir will be MassHealth's exclusive HCV therapy for about 80% of beneficiaries, MassHealth said, while Gilead's Sovaldi sofosbuvir and BMS's Daklinza daclatasvir will be indicated for a total of about 20%. ...